<DOC>
	<DOCNO>NCT00075712</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove ; give chemotherapy surgery may kill remain tumor cell . It yet know whether give chemotherapy surgery effective give chemotherapy surgery treat ovarian epithelial , fallopian tube , primary peritoneal cavity cancer . PURPOSE : This randomized phase II/III trial study well give chemotherapy surgery work compare give chemotherapy surgery alone treat patient newly diagnose advanced ovarian epithelial , fallopian tube , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Timing Surgery Chemotherapy Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility randomize trial determine impact time surgery chemotherapy patient newly diagnose advanced ovarian epithelial , primary peritoneal , fallopian tube cancer . OUTLINE : This randomize , pilot , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( primary surgery ) : Patients undergo radical surgery . Within 6 week primary surgery , patient receive chemotherapy comprise carboplatin alone combination paclitaxel another chemotherapy agent day 1 . Chemotherapy repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients may undergo interval debulking surgery third course chemotherapy . - Arm II ( neoadjuvant chemotherapy ) : Patients receive chemotherapy arm I 3 course . Within 3 week chemotherapy , patient undergo radical surgery . Within 6 week surgery , patient receive additional 3 course chemotherapy arm I . Patients follow 9 month randomization , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 100-150 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose advanced ovarian epithelial , primary peritoneal , fallopian tube cancer Clinical image evidence pelvic mass extrapelvic metastasis within past 4 week Serum CA 125/CEA ratio &gt; 25 Plans receive carboplatinbased chemotherapy PATIENT CHARACTERISTICS : Age Adult Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Considered fit undergo protocol treatment followup No prior concurrent malignancy would preclude study treatment comparison PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
</DOC>